Imeglimin hydrochloride

• CAT Number: I004854
• CAS Number: 775351-61-6
• Molecular Formula: C6H14ClN5
• Molecular Weight: 191.66
• Purity: ≥95%
• Target: AMPK
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: (4R)-6-N,6-N,4-trimethyl-1,4-dihydro-1,3,5-triazine-2,6-diamine;hydrochloride
• InChI: InChI=1S/C6H13N5.ClH/c1-4-8-5(7)10-6(9-4)11(2)3;/h4H,1-3H3,(H3,7,8,9,10);1H/t4-;/m1./s1
• InChIKey: UXHLCYMTNMEXKZ-PGMHMLKASA-N
• SMILES: CC1N=C(NC(=N1)N(C)C)N.Cl

Imeglimin (Cat No.:I004854) is a novel oral antidiabetic agent belonging to the glimins class. It contains a tetrahydro triazine structure and effectively targets the main abnormalities associated with type 2 diabetes. By acting on the liver, muscle, and pancreatic β-cells, Imeglimin addresses the key defects underlying the disease. This unique mechanism of action makes it a promising therapeutic option for individuals with type 2 diabetes.

Reference

[1]. Pirags V, et al. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012 Sep;14(9):852-8.
[2]. Fouqueray P, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013 Mar;36(3):565-8.